NEW YORK CITY, NY / ACCESS Newswire / November 8, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Avantor, Inc. ("Avantor" or the "Company") (NYSE:AVTR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged […]
NEW YORK CITY, NY / ACCESS Newswire / November 8, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against RCI Hospitality Holdings, Inc. ("RCI" or the "Company") (NASDAQ:RICK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail
NEW YORK CITY, NY / ACCESS Newswire / November 8, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Fortinet, Inc. ("Fortinet" or the "Company") (NASDAQ:FTNT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged
NEW YORK CITY, NY / ACCESS Newswire / November 8, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Synopsys, Inc. ("Synopsys" or the "Company") (NASDAQ:SNPS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged
NEW YORK CITY, NY / ACCESS Newswire / November 8, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ:JSPR) and certain officers.�� The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-08010,
Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo in patients who had atopic dermatitis and a history of asthma Extended dosing with rezpegaldesleukin q2w supports 24-week induction period for planned Phase 3 studies with improvement across major efficacy endpoints from Week 16 to 24, including EASI-75,
(NYSE:FCX), NEW YORK, Nov. 08, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Freeport-McMoRan Inc. (NYSE: FCX) resulting from allegations that Freeport may have issued materially misleading business information to the investing public. SO WHAT: If you
FCX Investor News: If You Have Suffered Losses in Freeport-McMoRan Inc. (NYSE: FCX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights GlobeNewswire November 08, 2025 NEW YORK, Nov. 08, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on
(NYSE:WPP), NEW YORK, Nov. 08, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares (“ADS” or “ADSs”) of WPP plc (NYSE: WPP) between February 27, 2025 and July 8, 2025, both dates inclusive (the “Class Period”), of the important December 8, 2025 lead plaintiff
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages WPP plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – WPP GlobeNewswire November 08, 2025 NEW YORK, Nov. 08, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares (“ADS” or “ADSs”) of